The research by Motoki Miyazawa et al. and Yoshiyuki Fujiwara et al., focusing on postoperative adjuvant treatment with KIF20A-containing peptide vaccines, has shown promising safety and immunogenicity, with significant survival benefits linked to KIF20A-specific CD8+ T-cell responses, offering a beacon of hope for surgically resected pancreatic cancer patients [97,98]. The gene discussed is KIF20A; the disease is familial pancreatic carcinoma.